Cite
HARVARD Citation
Schafer, E. et al. (2018). A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatric blood & cancer. 65 (8), p. n/a. [Online].